User:Mr. Ibrahem/Faricimab

Faricimab, sold under the brand name Vabysmo, is a medication used to treat wet age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is given by injection into the eye.

Common side effects include conjunctival bleeding. Other side effects may include eye infection and allergic reactions. Use is not recommended in pregnancy. It is a monoclonal antibody, that blocks both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), thus decreasing new blood vessel growth in the eye.

Faricimab was approved for medical use in the United States and Europe in 2022. In the United Kingdom a 28.8 mg vial costs the NHS about £860. In the United States 6 mg costs about 2,300 USD as of 2022.